Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • Anthony.287
    Member
    • Dec 2010
    • 95

    #1

    Revisiting Linux distributions...

    Morning!
    First, a bit of background. Currently, my lab (a core facility) is using the 454 FLX+. Our data rig, which we use for the Roche software suite and not much else, is running RHEL 6, and our purchase with Red Hat has expired. RHEL has been quite a pain, what with the dependencies and all, and our lack of an in-house Linux expert. I’m currently trying to get QIIME up and running, but our subscription to Red Hat has expired so we have no support, which means I can’t update software or acquire the dependencies needed for QIIME. There has been some talk of moving from the 454 to an Illumina platform, but that could be years in the future.
    I guess my question is – should we renew our RHEL subscription, or move to a different Linux distribution? We’d like to be able to provide as much bioinformatics to our clients as possible, as painlessly as possible, and not have to worry about this for a long time.
    Thank you!!
  • molecules
    MU Informatics Research Core F
    • Oct 2010
    • 6

    #2
    CentOS (http://www.centos.org/) is the effectively the same thing as RHEL. It doesn't come with support, but it is free.

    Comment

    • molecules
      MU Informatics Research Core F
      • Oct 2010
      • 6

      #3
      However, if you don't have a Linux expert on hand, it may be worth paying RHEL for support. That's a decision you'll have to make.

      Comment

      • TonyBrooks
        Senior Member
        • Jun 2009
        • 303

        #4
        The disadvantage of switching from RHEL is that AFAIK that and Fedora are the only distros supported by Roche. I generally steer clear of Fedora as it's lifespans are typically short (new versions every 6 months and package maintenance for about a year)

        If you do move away, the best ones to go for is either CentOS or Ubuntu but initial set up may be more complicated than it is than the push-button installs in RHEL/Fedora.
        Having said that, there are walkthroughs for install on non supported distos;

        Pyrosequencing in picotiter plates, custom arrays for enrichment/decomplexing. (Roche)

        Comment

        • GenoMax
          Senior Member
          • Feb 2008
          • 7142

          #5
          Have you checked around to see if there is a campus license for RedHat available (if you are at an academic campus that is a possibility) that you could take advantage of?

          I may get flamed for saying this but if you have no in house expertise on linux administration (and have managed to keep your server afloat/secure so far with RHEL) then the path of least resistance would be to bite the bullet and buy the RHEL maintenance. Fully justifiable, if Roche is your main (only?) business.

          If you do manage to install Roche software on an unsupported OS, any time there is a problem Roche tech support would likely throw up their hands and say that you are on your own.

          Comment

          • andylemire
            Member
            • Jan 2014
            • 14

            #6
            There's only about two and a half years left with 454 support anyway (mid-2016). Seems to me that buying into RHEL for another year or two to support this platform during its phase out is kicking the can down the road, but then again we do sequencing with the sequencers we have, not the sequencers we might wish to have at some point in the future...or something like that.

            Comment

            Latest Articles

            Collapse

            • SEQadmin2
              Multiomic Liquid Biopsy: What DNA/RNA Panels Reveal That DNA Alone Can’t
              by SEQadmin2



              Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?

              Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating
              ...
              10-14-2026, 09:55 AM
            • SEQadmin2
              New Genomics Technologies Take Aim at Long-Standing Limits
              by SEQadmin2


              Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.

              We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing
              ...
              09-28-2026, 10:25 AM

            ad_right_rmr

            Collapse

            News

            Collapse

            Topics Statistics Last Post
            Started by SEQadmin2, Yesterday, 11:13 AM
            0 responses
            21 views
            0 reactions
            Last Post SEQadmin2  
            Started by SEQadmin2, Yesterday, 10:48 AM
            0 responses
            18 views
            0 reactions
            Last Post SEQadmin2  
            Started by SEQadmin2, 10-15-2026, 10:52 AM
            0 responses
            36 views
            0 reactions
            Last Post SEQadmin2  
            Started by SEQadmin2, 10-14-2026, 05:39 AM
            0 responses
            42 views
            0 reactions
            Last Post SEQadmin2  
            Working...